M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Clinical trial NCT06177041 · RECRUITING

Trial details

NCT number: NCT06177041
Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced Unresectable or Metastatic Gastric Cancer Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Start date: 2023-12-25
Primary completion: 2027-01-11
Enrollment: 486

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.